Dec. 20, 2024
| Today’s news and insights for medtech leaders
|
NOTE FROM THE EDITOR
MedTech Dive will take a publishing break over the next two weeks for the holidays. We will return to our regular schedule on Thursday, Jan. 2.
Over this time, look out for three special edition newsletters that will run while we’re away: On Dec. 23, we’ll publish a recap of the medtech industry’s top news in 2024, and on Dec. 27, we’ll take a look at the top trends. Finally, on Dec. 30, we’ll publish a newsletter reviewing the industry’s most notable M&A deals of the year.
If you’re already planning for 2025, check out our list of the biggest medical device conferences to attend next year.
Love the newsletter? Become an exclusive Dive Insider. Make sure your colleagues and peers are reading too. Share this link with them to get signed up for the newsletter: https://www.medtechdive.com/signup/insiders/?signup_referred_by=628afe06d475ec72a306837a
Have a wonderful holiday season!
|
Inspectors found 111 open tickets for software defects categorized as catastrophic or severe patient harm. Several safety complaints were also listed that BD didn’t report within the required timeframe.
|
Edwards submitted a request for a national coverage determination in February, after receiving FDA approval for its Evoque device earlier that month.
|
IPOs in medtech have been sparse, but some analysts said improving market conditions could support a revival of offerings in 2025.
|
From challenging market leaders to the growing influence of artificial intelligence, medical device executives had a lot to discuss this year. Check out MedTech Dive’s top Q&As of 2024.
|
The update followed a higher than expected number of reports of esophageal injury after catheter ablation procedures for atrial fibrillation.
|
Joseph Wright’s resignation is effective in January, and CEO and founder Fred Lampropoulos has been reappointed president.
|
|
Getting your medical device to market takes purpose-built technology, strategic planning, and experienced partners. Explore trial complexities, including regulatory trends and best practices, in this playbook.
|
|
From Our Library
Trendline
Supported by IQVIA
|
View all resources
What We're Reading
| 
